New Weight-Loss shot enters human testing
NCT ID NCT06493084
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called LAE102, given as an injection, in healthy volunteers and people who are overweight or obese. The main goal is to check if the drug is safe and how the body processes it. Researchers will also look for early signs of weight-related effects. The study involves 160 participants and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LAE102 injection
- What this could lead to
- If this early trial shows LAE102 is safe, it could lead to a new injectable medication for weight management in people who are overweight or obese.
- What could go wrong
- This is a very early Phase 1 study with only 160 participants, focused on safety and dosing. It is not designed to prove weight loss, and many drugs fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESE VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan Zhongshan Hospital
RECRUITINGShanghai, Shanghai Municipality, 201203, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.